Table of Contents
During the Covid-19 pandemic, emergency use authorizations (EUAs) played a crucial role in providing access to antiviral treatments quickly. These authorizations allowed health authorities to make promising medications available to the public before full formal approval, helping to manage the crisis more effectively.
What is an Emergency Use Authorization?
An EUA is a mechanism used by regulatory agencies like the U.S. Food and Drug Administration (FDA) to facilitate the availability of medical countermeasures during public health emergencies. It permits the use of unapproved medical products or unapproved uses of approved products when certain criteria are met.
Criteria for Issuing an EUA
- The situation must pose a significant or emergency health risk.
- The evidence must suggest that the product may be effective in diagnosing, treating, or preventing the disease.
- The known and potential benefits should outweigh the known and potential risks.
- No adequate, approved, and available alternatives should exist.
Covid Antivirals and EUAs
Several antiviral medications received EUAs during the Covid-19 pandemic. These drugs were authorized for use based on preliminary data indicating they could reduce the severity or duration of illness.
Examples of Authorized Antivirals
- Remdesivir (Veklury): Used for hospitalized patients with severe Covid-19.
- Paxlovid (nirmatrelvir with ritonavir): An oral antiviral for high-risk patients.
- Molnupiravir: An oral antiviral authorized for certain cases.
Limitations and Considerations
EUAs are not equivalent to full FDA approval. They are based on the best available evidence at the time and are subject to ongoing review. Safety and effectiveness data continue to be collected even after authorization.
The Future of EUAs
As more data becomes available, some EUAs may transition to full approval. This process ensures that treatments are safe and effective before they are widely adopted in standard medical practice.